Connect Biopharma Holdings Limited
CNTB
$2.45
-$0.23-8.58%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 64.00K | 762.00K | 1.97M | 26.03M | 26.03M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 64.00K | 762.00K | 1.97M | 26.03M | 26.03M |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | 64.00K | 762.00K | 1.97M | 26.03M | 26.03M |
| SG&A Expenses | 20.34M | 20.18M | 18.55M | 18.27M | 17.43M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 58.14M | 52.93M | 48.50M | 44.10M | 45.29M |
| Operating Income | -58.07M | -52.17M | -46.54M | -18.07M | -19.25M |
| Income Before Tax | -55.28M | -49.00M | -44.68M | -16.96M | -15.41M |
| Income Tax Expenses | 197.00K | 276.00K | 272.00K | 247.00K | 223.00K |
| Earnings from Continuing Operations | -55.48 | -49.28 | -44.95 | -17.21 | -15.63 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -55.48M | -49.28M | -44.95M | -17.21M | -15.63M |
| EBIT | -58.07M | -52.17M | -46.54M | -18.07M | -19.25M |
| EBITDA | -57.37M | -51.49M | -45.86M | -17.40M | -18.59M |
| EPS Basic | -1.00 | -0.89 | -0.81 | -0.31 | -0.28 |
| Normalized Basic EPS | -0.62 | -0.55 | -0.48 | -0.16 | -0.14 |
| EPS Diluted | -1.00 | -0.89 | -0.81 | -0.31 | -0.28 |
| Normalized Diluted EPS | -0.62 | -0.55 | -0.48 | -0.16 | -0.14 |
| Average Basic Shares Outstanding | 222.64M | 221.88M | 221.41M | 221.10M | 220.85M |
| Average Diluted Shares Outstanding | 222.64M | 221.88M | 221.41M | 221.63M | 221.38M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |